- An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias — Active Not Recruiting • Phase I / Phase II • NCT05757570.
- New drug povetacicept tested in adults with autoimmune blood disorders to assess safety and effectiveness over six months.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
The goal of this clinical study is to evaluate povetacicept in adults with autoimmune cytopenias of immune thrombocytopenia, autoimmune hemolytic anemia, and cold agglutinin disease to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment period participants will receive povetacicept approximately every 4 weeks for 6 months, with the possibility of participating in a 6-month study treatment extension period. Conditions: Immune Thrombocytopenia, Idiopathic Thrombocytopenic Purpura, Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease Interventions: povetacicept Lead Sponsor: Alpine Immune Sciences, Inc. Planned Enrollment: 30…